علاج التهاب الرئة المرتبط بالتنفس الاصطناعي الناجم عن Pseudomonas aeruginosa — في غياب الصدمة الإنتانية مع توافر نتائج اختبار الحساسية

References

DOI: 10.1093/cid/ciw353

• For patients with HAP/VAP due to P. aeruginosa who are not in septic shock or at a high risk for death, and for whom the results of antibiotic susceptibility testing are known, we recommend monotherapy using an antibiotic to which the isolate is susceptible rather than combination therapy (strong recommendation, low-quality evidence).
• High risk of death in the meta-regression analysis was defined as mortality risk >25%; low risk of death is defined as mortality risk <15%.
• For patients with HAP/VAP due to P. aeruginosa, we recommend that the choice of an antibiotic for definitive (not empiric) therapy be based upon the results of antimicrobial susceptibility testing (strong recommendation, low-quality evidence).